Remove patients making-pharmacy-first-work-need-further-innovation
article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

We live in unprecedented times, where innovation in biosciences continues to accelerate. Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. Why current patient access solutions have come up short. Yet, the healthcare experience is antiquated.

article thumbnail

Moderna takes aim at global expansion plans with manufacturing ramp-up

Pharmaceutical Technology

However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. In a January business update , the company predicted it will make a minimum of $5 billion in new vaccine sales. In 2021, Moderna had a net income of $12.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

To help solve patient distrust in pharma, industry collaboration is key

pharmaphorum

This is a stark reminder that the industry still has further to go to convince patients it is working in their best interests. Pharma can only continue to grow their business models, and deliver faster for our growing population, if the public trusts the industry to deliver against their needs.

article thumbnail

Accelerating the adoption of innovation in the NHS

pharmaphorum

Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. Our main focus is improving outcomes for patients by getting more rapid uptake of advances in life science technology and service reorganisation.”.

article thumbnail

What we’re expecting in 2021, and beyond…

pharmaphorum

It’s swept aside several historic barriers to uptake, such as the healthcare professional and patient desire to physically meet, medical guidelines that focus on in-person diagnosis and reimbursement models that discourage remote consultation. As such, reps will need to be reskilled. As such, reps will need to be reskilled.

article thumbnail

From trial design for patients to trial design with patients: a key topic at DIA ’22

pharmaphorum

At the 2022 Drug Information Association (DIA) annual meeting last week, it was inspiring to connect with fellow research and development (R&D) stakeholders, regulators, health and digital data partners and more to navigate challenges in drug development that impact patients globally. Patient journey. Patient access.

Trials 62
article thumbnail

Beyond blood tests: The evolution of digital biomarkers in clinical research

Drug Discovery World

They mark a significant shift in clinical research, utilising technology to capture real-time patient data. The study’s app intermittently checked for irregular pulses and those flagged were further monitored through an ECG patch, confirming AF in 34% of flagged cases 5. The potential of these digital tools is vast.